Key Aspects of Modern Drug Discovery
This training event aimed to provide a comprehensive overview of the pre-clinical drug discovery process. Designed and delivered by experts from industry and academia, the event was suitable for recent graduates, PhD students and early career scientists interested in working in the pre-clinical drug discovery industry.
The course focused on small molecule target identification and validation, hit-to-lead and lead optimisation, as well as on pre-clinical drug development and toxicology. ‘Key aspects of modern drug discovery’ comprised lectures, case studies, group discussions and a drinks reception to encourage networking and collaboration among delegates and speakers.
- Rick Davies, AstraZeneca
- Jacqui Piner, GSK
- John Unitt, Sygnature Discovery
- Heather Wallace, University of Aberdeen
- Rupert Satchell, Sygnature Discovery
- Andy Davis, AstraZeneca
- John Ladbury, University of Leeds
The event was developed in collaboration with the Royal Society of Chemistry, and supported by the Royal Society of Biology and the British Pharmacological Society.